EPIRUS Biopharmaceuticals Valuation
| EPRSQDelisted Stock | USD 0.0001 0.00 0.00% |
EPIRUS Biopharmaceutica seems to be overvalued based on Macroaxis valuation methodology. Our model computes the value of EPIRUS Biopharmaceuticals from examining the firm fundamentals such as operating margin of (37.45) %, and Shares Outstanding of 26.18 M as well as evaluating its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that EPIRUS Biopharmaceutica's price fluctuation is very steady at this time. Calculation of the real value of EPIRUS Biopharmaceuticals is based on 3 months time horizon. Increasing EPIRUS Biopharmaceutica's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
EPIRUS Biopharmaceutica's intrinsic value may or may not be the same as its current market price of 0.0001, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.5E-5 | Hype 1.0E-4 |
The intrinsic value of EPIRUS Biopharmaceutica's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence EPIRUS Biopharmaceutica's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of EPIRUS Biopharmaceuticals helps investors to forecast how EPIRUS pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of EPIRUS Biopharmaceutica more accurately as focusing exclusively on EPIRUS Biopharmaceutica's fundamentals will not take into account other important factors: EPIRUS Biopharmaceutica Total Value Analysis
EPIRUS Biopharmaceuticals is currently projected to have takeover price of (6 M) with market capitalization of 157, debt of 14.85 M, and cash on hands of 20.86 M. The negative valuation of EPIRUS Biopharmaceutica may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should thoroughly investigate all of the EPIRUS Biopharmaceutica fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(6 M) | 157 | 14.85 M | 20.86 M |
EPIRUS Biopharmaceutica Investor Information
The company has price-to-book (P/B) ratio of 0.0. Some equities with similar Price to Book (P/B) outperform the market in the long run. EPIRUS Biopharmaceuticals recorded a loss per share of 2.53. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 16th of July 2014. Based on the key measurements obtained from EPIRUS Biopharmaceutica's financial statements, EPIRUS Biopharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.EPIRUS Biopharmaceutica Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. EPIRUS Biopharmaceutica has an asset utilization ratio of 0.97 percent. This connotes that the Company is making $0.009701 for each dollar of assets. An increasing asset utilization means that EPIRUS Biopharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.EPIRUS Biopharmaceutica Profitability Analysis
The company reported the revenue of 701 K. Net Loss for the year was (52.19 M) with profit before overhead, payroll, taxes, and interest of 576 K.About EPIRUS Biopharmaceutica Valuation
The pink sheet valuation mechanism determines EPIRUS Biopharmaceutica's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of EPIRUS Biopharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of EPIRUS Biopharmaceutica. We calculate exposure to EPIRUS Biopharmaceutica's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of EPIRUS Biopharmaceutica's related companies.EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts. EPIRUS BIOPHARMACEUTICA operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 73 people.
8 Steps to conduct EPIRUS Biopharmaceutica's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates EPIRUS Biopharmaceutica's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct EPIRUS Biopharmaceutica's valuation analysis, follow these 8 steps:- Gather financial information: Obtain EPIRUS Biopharmaceutica's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine EPIRUS Biopharmaceutica's revenue streams: Identify EPIRUS Biopharmaceutica's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research EPIRUS Biopharmaceutica's industry and market trends, including the size of the market, growth rate, and competition.
- Establish EPIRUS Biopharmaceutica's growth potential: Evaluate EPIRUS Biopharmaceutica's management, business model, and growth potential.
- Determine EPIRUS Biopharmaceutica's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate EPIRUS Biopharmaceutica's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
EPIRUS Biopharmaceutica Growth Indicators
Investing in growth stocks can be very risky. If the company such as EPIRUS Biopharmaceutica does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Retained Earnings | -138.8 M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in EPIRUS Pink Sheet
If you are still planning to invest in EPIRUS Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EPIRUS Biopharmaceutica's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |